Skip to main content

Advertisement

Log in

Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To examine the factors affecting the efficacy of infliximab (IFX) as a treatment for uveitis in Behçet’s disease.

Methods

Clinical records of 29 patients with refractory uveoretinitis were examined retrospectively for the period between 6 months before the initiation of IFX therapy to 12 months thereafter. The patients were divided into two groups based on the absence (Group 1) or occurrence (Group 2) of ocular inflammatory attacks during the observation period after IFX therapy, and the clinical records of the groups were compared

Results

The mean age at onset of ocular inflammation in Group 1 patients (n = 17) was lower than that in Group 2 patients (n = 12) (p = 0.023). Compared to Group 2 patients, the period from onset to IFX therapy in Group 1 was longer (p = 0.037), and the frequency of ocular inflammatory attacks before IFX therapy was lower (p = 0.013). The rates of ocular fundus attacks before IFX therapy were 0.82 ± 0.28 in Group 1 and 0.96 ± 0.10 in Group 2 (p = 0.040). Three of 33 (9.1 %) eyes in Group 1 and nine of 24 eyes (37.5 %) in Group 2 had an improved best-corrected visual acuity of >0.2 logarithm of the minimal angle resolution (p < 0.01).

Conclusions

Patients in Group 1 tended to have fewer intraocular attacks (fewer fundus attacks in particular) prior to IFX therapy and have a longer period from onset of intraocular inflammation to IFX therapy. The improvement of the BCVA in Group 2 tended to be better.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med. 1999;341:1284–91.

    Article  PubMed  CAS  Google Scholar 

  2. Behçet’s Disease Research Committee of Japan. The revised criteria and manual of treatments of Behçet’s Disease (in Japanese). Tokyo: Ministry of Health and Welfare; 2003. p. 11–29.

  3. Mochizuki M. Immunotherapy for Behçet’s disease. Int Rev Immunol. 1997;14:49–66.

    Article  PubMed  CAS  Google Scholar 

  4. Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, et al. Cytokine production profile in patients with Behçet’s disease treated with infliximab. Cytokine. 2003;24:210–8.

    Article  PubMed  CAS  Google Scholar 

  5. Eliott MJ, Mani RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet. 1994;344:1125–7.

    Article  Google Scholar 

  6. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet. 2002;359:1541–9.

    Article  PubMed  CAS  Google Scholar 

  7. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272–84.

    Article  PubMed  CAS  Google Scholar 

  8. Heldmann F, Brandt J, van der Horst-Bruinsma IE, Landewe R, Sieper J, Burmester GR, et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol. 2011;29:672–80.

    PubMed  CAS  Google Scholar 

  9. Reinisch W, Van Assche G, Befrits R, Connell W, D’Haens G, Ghosh S, et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis. 2012;6:248–58.

    Article  PubMed  Google Scholar 

  10. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol. 2010;94:284–8.

    Article  PubMed  Google Scholar 

  11. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol. 2008;146:845–50.

    Article  PubMed  CAS  Google Scholar 

  12. Takamoto M, Kaburaki T, Numaga J, Fujino Y, Kawashima H. Long-term infliximab treatment for Behçet’s disease. Jpn J Ophthalmol. 2007;51:239–40.

    Article  PubMed  Google Scholar 

  13. Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M. Safety and efficacy of infliximab therapy in active Behcet’s uveitis: an open-label trial. Rheumatol Int. 2008;29:53–7.

    Article  PubMed  CAS  Google Scholar 

  14. Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behçet’s disease. Jpn J Ophthalmol. 2007;51:191–6.

    Article  PubMed  CAS  Google Scholar 

  15. Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-ArfajA. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet’s disease. Int Ophthalmol. 2005;26:83–92.

  16. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum. 2005;52:2478–84.

    Article  PubMed  CAS  Google Scholar 

  17. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–8.

    PubMed  CAS  Google Scholar 

  18. Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, Schlincker A, Martín-Mola E. Effect of infliximab on threatening panuveitis in Behçet’s disease. Lancet. 2001;358:1644.

    Article  PubMed  Google Scholar 

  19. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet. 2001;358:295–6.

    Article  PubMed  CAS  Google Scholar 

  20. Tanaka H, Sugita S, Yamada Y, Kawaguchi T, Iwanaga Y, Kamoi K, et al. Effects and safety of infliximab administration in refractory uveoretinitis with Behçet’s disease (in Japanese). Nippon Ganka Gakkai Zasshi. 2010;114:87–95.

    PubMed  Google Scholar 

  21. Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behçet’s disease. Br J Ophthalmol. 2011;95:549–52.

    Article  PubMed  Google Scholar 

  22. Kaburaki T, Takamoto M, Numaga J, Kawashima H, Araie M, Ohnogi Y, et al. Genetic association of HLA-A*2601 with ocular Behçet’s disease in Japanese patients. Clin Exp Rheumatol. 2010;28:39–44. Epub.

    Google Scholar 

  23. Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, et al. Comparison of patients with Behçet’s disease in the 1980s and 1990s. Ophthalmology. 2004;111:810–5.

    Article  PubMed  Google Scholar 

  24. Kaburaki T, Araki F, Takamoto M, Okinaga K, Yoshida A, Numaga J, et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet’s disease. Graefes Arch Clin Exp Ophthalmol. 2010;248:709–14.

    Article  PubMed  Google Scholar 

  25. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoids edema associated with uveitis. Am J Ophthalmol. 2004;138:648–50.

    Article  PubMed  CAS  Google Scholar 

  26. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology. 2007;46:1828–34.

    Article  PubMed  CAS  Google Scholar 

  27. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711–5.

    Article  PubMed  Google Scholar 

  28. Baert F, Noman M, Vermeire S, Van Assche G, D’ Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–8.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Atsushi Yoshida.

About this article

Cite this article

Yoshida, A., Kaburaki, T., Okinaga, K. et al. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy. Jpn J Ophthalmol 56, 536–543 (2012). https://doi.org/10.1007/s10384-012-0182-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-012-0182-z

Keywords

Navigation